BRCA2 and triple-negative breast carcinoma: The Treating to New Targets trial did not demonstrate a role for HRD testing to identify patients with wild-type BRCA1 and BRCA2 who have advanced triple-negative breast cancer more likely to benefit from carboplatin as opposed to taxane chemotherapy25.